Company profile for Chiesi Group

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of €1,768 millions we are among the top 50 pharmaceutical companies in the world. Our production sites are in Parma, Italy, Blois (France) and ...
We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas. With a turnover of €1,768 millions we are among the top 50 pharmaceutical companies in the world. Our production sites are in Parma, Italy, Blois (France) and Santana De Parnaiba (Brazil). Its R&D centres in Parma (Italy), Paris (France), Cary (USA), Chippenham and Oxford (UK) and Lidingö (Sweden) part of the acquisition of protein therapeutics biotech Zymenex in 2013.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Italy
Address
Address
26/A, Via Palermo (Main entrance: 1, Via Giacomo Chiesi) 43122 Parma
Telephone
Telephone
+39 0521 2791
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.globenewswire.com/news-release/2025/11/12/3186250/0/en/Chiesi-Group-Enters-into-an-Exclusive-License-Agreement-with-Aliada-Therapeutics-a-Wholly-Owned-Subsidiary-of-AbbVie-to-Advance-Blood-Brain-Barrier-Crossing-Platform-Technology-in-.html

GLOBENEWSWIRE
13 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-13/procysbi-gastro-resistant-mercaptamine-recommended-for-use-in-nhs-scotland-for-the-treatment-of-nephropathic-cystinosis

PHARMIWEB
13 Nov 2025

https://www.pharmiweb.com/press-release/2025-11-04/chiesi-inaugurates-the-expansion-of-its-industrial-site-in-la-chaussée-saint-victor-a-strategic-investment-towards-sustainable-respiratory-options-f

PHARMIWEB
04 Nov 2025

https://www.globenewswire.com/news-release/2025/10/15/3167051/0/en/Chiesi-Announces-FDA-Acceptance-of-New-Drug-Application-for-its-Triple-Combination-Inhaler-for-the-Maintenance-Treatment-of-Asthma.html

GLOBENEWSWIRE
15 Oct 2025

https://www.prnewswire.com/news-releases/pantherx-rare-selected-by-chiesi-for-the-distribution-of-mycapssa-302582168.html

PR NEWSWIRE
13 Oct 2025

https://www.biospace.com/business/chiesi-arbor-weave-2-1b-rare-disease-pact

BIOSPACE
06 Oct 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty